We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Despite their frequency, head and neck cancers often evade early detection, presenting silently until they reach advanced ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...

Katharine Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group ... “We are optimistic about the potential of Versamune ® HPV in combination with pembrolizumab to enhance ...

Head and neck surgeon Dr Matthew Old raised the alarm over rapidly rising rates of HPV-related head and neck cancers which affect the tonsils and tongue. He said that if this trend continues ...

The majority of people are unaware that the human papillomavirus (HPV) is more common among men and is associated wi ...

These vaccines are nearly 100% effective if they're given prior to exposure to the HPV types they cover. And this is why the ...

The study "Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in HPV-negative head and neck cancer: The DEPEND Phase 2 nonrandomized clinical trial ...